Recursion Pharmaceuticals (RXRX) Financial Analysis & Valuation | Quarter Chart

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in... more
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the d... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$1.68BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEONajat Khan
IPO Date2021-04-16CAGR87.64%
Employees600Websitewww.recursion.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
RXRX chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$1.46BP/E-3.08Forward P/E-3.58PEG
P/S80.51P/B4.9P/CF-10.34P/FCF-10.19
Sales$54.85MSales 1Y-14.88%Sales 3Y9.98%Sales 5Y552.03%
EPS$-1.04EPS 1Y-41.57%EPS 3Y-22.96%EPS 5Y42.12%
Sales QoQ18.51%EPS QoQ13.64%Sales QoQ Avg112.63%EPS QoQ Avg-8.87%
Gross Margin-46.66%Operating Margin-991.72%Profit Margin-945.92%ROCE-49.78%
ROA-43%ROE-50%Altman Z Score-0.28Piotroski Score3
Current Ratio5.03Quick Ratio5.03Cash Ratio4.55Op. CF Ratio-1.56
Debt/Equity0.07Debt/Assets0.05Lt Debt/Equity0.04Lt Debt/Cap.
Intrst Cov.-459.86Inventory TurnoverAsset Turnover0.05Receivables Turnover3.81
Enterprise Value$1.46BP/E Ratio-3.08
Forward P/E-3.58PEG Ratio
P/S Ratio80.51P/B Ratio4.9
P/CF Ratio-10.34P/FCF Ratio-10.19
EPS$-1.04EPS Growth 1Y-41.57%
EPS Growth 3Y-22.96%EPS Growth 5Y42.12%
Revenue Growth 1Y-14.88%Gross Margin-0.47%
Operating Margin-9.92%Profit Margin-9.46%
ROE-0.5%ROA-0.43%
ROCE-0.5%Current Ratio5.03
Quick Ratio5.03Cash Ratio4.55
Debt/Equity0.07Interest Coverage-459.86
Altman Z Score-0.28Piotroski Score3

Recursion Pharmaceuticals (RXRX) valuation & financials

Recursion Pharmaceuticals (RXRX) has a market capitalization of $1.68B and trades at a price-to-earnings ratio of -3.1. It operates in the Healthcare sector (Biotechnology).

Recursion Pharmaceuticals's revenue grew -14.9% over the last year.

Recursion Pharmaceuticals's next earnings report is scheduled for November 4, 2026 before market open; analysts estimate EPS of $-0.24. Check the earnings calendar to see all companies reporting this week.

📈 Analysts estimate RXRX EPS of $-0.24 for the upcoming quarter. See Recursion Pharmaceuticals revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Recursion Pharmaceuticals (RXRX) — frequently asked questions

When does Recursion Pharmaceuticals (RXRX) report earnings next?

Recursion Pharmaceuticals is expected to report earnings on November 4, 2026 before market open. Analysts estimate EPS of $-0.24.

What is Recursion Pharmaceuticals's market cap?

Recursion Pharmaceuticals (RXRX) has a market capitalization of $1.68B.

What is RXRX's P/E ratio?

Recursion Pharmaceuticals trades at a price-to-earnings ratio of -3.1, with trailing twelve-month EPS of $-1.04.

How fast is Recursion Pharmaceuticals growing?

Recursion Pharmaceuticals's revenue grew -14.9% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)